Abstract
Immunological manipulations are the basis for modern treatments of autoimmune diseases (AID). Targeted immune suppression with lymphopenic based chemotherapy, and monoclonal anti B or T lymphocytic antibodies, are integral part of the conditioning for stem cell transplantation (SCT). Immune manipulation by Cyclophosphamide (Cy), ATG, Campath and recently rituximab (RI), with or without stem cell support are the basis for emerging therapeutic modalities aiming to eradicate the autoreactive clone in various autoimmune disorders. Couple of hundreds of SCTs have been recently performed in various autoimmune disorders, mainly multiple sclerosis (MS), progressive systemic sclerosis (PSS), systemic lupus erythematosis (SLE) and rheumatoid arthritis (RA). Preliminary results are encouraging. Better selection of patients and earlier treatment, before irreversible organ failure develops will probably improve results. Current ongoing multicenter studies are evaluating the role of SCT in MS, RA, SLE, and PSS.
Keywords: autoimmune disease, rituximab, campath-1h, stem cell transplantation, systemic iupus erythematosus, rheumatoid arthritis, scleroderma, multiple sclerosis
Current Pharmaceutical Design
Title: Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Volume: 9 Issue: 3
Author(s): Yossi Cohen, Aaron Polliack and Arnon Nagler
Affiliation:
Keywords: autoimmune disease, rituximab, campath-1h, stem cell transplantation, systemic iupus erythematosus, rheumatoid arthritis, scleroderma, multiple sclerosis
Abstract: Immunological manipulations are the basis for modern treatments of autoimmune diseases (AID). Targeted immune suppression with lymphopenic based chemotherapy, and monoclonal anti B or T lymphocytic antibodies, are integral part of the conditioning for stem cell transplantation (SCT). Immune manipulation by Cyclophosphamide (Cy), ATG, Campath and recently rituximab (RI), with or without stem cell support are the basis for emerging therapeutic modalities aiming to eradicate the autoreactive clone in various autoimmune disorders. Couple of hundreds of SCTs have been recently performed in various autoimmune disorders, mainly multiple sclerosis (MS), progressive systemic sclerosis (PSS), systemic lupus erythematosis (SLE) and rheumatoid arthritis (RA). Preliminary results are encouraging. Better selection of patients and earlier treatment, before irreversible organ failure develops will probably improve results. Current ongoing multicenter studies are evaluating the role of SCT in MS, RA, SLE, and PSS.
Export Options
About this article
Cite this article as:
Cohen Yossi, Polliack Aaron and Nagler Arnon, Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support, Current Pharmaceutical Design 2003; 9 (3) . https://dx.doi.org/10.2174/1381612033392134
DOI https://dx.doi.org/10.2174/1381612033392134 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual Targeting of Autophagy and NF-κB Pathway by PPARγ Contributes to the Inhibitory Effect of Demethoxycurcumin on NLRP3 Inflammasome Priming
Current Molecular Pharmacology Nontuberculous Mycobacterium Infections in Rheumatoid Arthritis Patients: The Serodiagnosis of Pulmonary Disease due to Mycobacterium avium Complex with an Enzyme Immunoassay Kit Detecting Glycopeptidolipid Core Antigen (Capilia MAC Antibody ELISA)<sup>®</sup>)
Current Rheumatology Reviews Inflammatory Mediators as Potential Therapeutic Targets in the Spine
Current Drug Targets - Inflammation & Allergy Development of Standardized <i>Cyanthillium cinereum</i> (L.) H.Rob. Extract and Determination of its Biological Activities
The Natural Products Journal Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Use of Drugs that Target Neural-Immune Pathways in the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Patent Selections
Recent Patents on Nanomedicine The Association of Collagenase with Human Diseases and its Therapeutic Potential in Overcoming them
Current Biotechnology Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Thrombomodulin – A New Target for Treating Stroke at the Crossroad of Coagulation and Inflammation
Current Medicinal Chemistry Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry Osteoarthritis: Is there a Window of Opportunity
Current Rheumatology Reviews QbD-Enabled Systematic Development of Ileo-Colonic Targeted Novel Mucoadhesive Microspheres of Flurbiprofen
Current Drug Delivery Glycomics: Relevance for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Human Interleukin-19: Structure, Function and Disease Associations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry